Clinical Trial Update: Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update on Inetetamab combined with anti-PD-1 antibody and albumin-bound paclitaxel for HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Anti-PD-1 Monoclonal Antibody
• Inetetamab (inetetamab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 4 | Status: UNKNOWN